What is Stoke Therapeutics, Inc.'s D&A?

Stoke Therapeutics, Inc. (STOK) reported D&A of $439K in Q1 2026.

How has Stoke Therapeutics, Inc.'s D&A changed year-over-year?

Stoke Therapeutics, Inc.'s D&A decreased by 8.0% year-over-year, from $477K to $439K.

What is the long-term trend for Stoke Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s D&A has grown at a 16.1% compound annual growth rate (CAGR), from $974K to $1.77M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Stoke Therapeutics, Inc. STOK D&A

D&A at other companies

Ionis PharmaceuticalsIONS

$3.3M+48.2%

Jazz PharmaceuticalsJAZZ

$9.1M-12.5%

Xenon PharmaceuticalsXENE

$587K-10.9%

Praxis Precision Medicines, Inc.PRAX

$39K-17.0%

Harmony Biosciences Holdings, Inc.HRMY

$7K0.0%

Nurix Therapeutics, Inc.NRIX

$2.2M-6.6%

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s D&A?: Stoke Therapeutics, Inc. (STOK) reported D&A of $439K in Q1 2026.
How has Stoke Therapeutics, Inc.'s D&A changed year-over-year?: Stoke Therapeutics, Inc.'s D&A decreased by 8.0% year-over-year, from $477K to $439K.
What is the long-term trend for Stoke Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s D&A has grown at a 16.1% compound annual growth rate (CAGR), from $974K to $1.77M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.